Skip to main content
Clinical Trials/NCT00346528
NCT00346528
Completed
Phase 3

Safety of NGOIS Compared to BSS Plus in Pediatric Patients

Alcon Research1 site in 1 country18 target enrollmentStarted: July 2006Last updated:

Overview

Phase
Phase 3
Status
Completed
Enrollment
18
Locations
1
Primary Endpoint
Safety Variables: Endothelial cell density, visual acuity, intraocular pressure, ocular signs and fundus assessment

Overview

Brief Summary

To evaluate the Safety of Next Generation Ophthalmic Irrigating Solution compared to BSS Plus for use during cataract surgery in Pediatric patients.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
1 Week to 17 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Cataract present.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

  • As per age requirements.
  • Other protocol-defined exclusion criteria may apply.

Arms & Interventions

NGOIS

Experimental

Intervention: Next Generation Ophthalmic Irrigating Solution (NGOIS) (Drug)

BSS Plus

Active Comparator

Intervention: BSS Plus (Drug)

Outcomes

Primary Outcomes

Safety Variables: Endothelial cell density, visual acuity, intraocular pressure, ocular signs and fundus assessment

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials